In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Judy Olian Biography and Net Worth

Director of United Therapeutics

Dr. Olian is a Director of Ares Management Corporation. Dr. Olian currently serves as the President of Quinnipiac University. Previously, Dr. Olian served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from January 2006 to July 2018. Prior to her tenure at UCLA, Dr. Olian served as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Her business expertise centers on aligning organizations' design with market opportunities, developing strategically coherent human resource systems and incentives, and managing top management teams. Dr. Olian serves as a member of the Business Higher Education Forum, the New Haven Promise (a nonprofit board), which works with low income children in the community, and Catalyst, a global think tank for women in business. Dr. Olian also serves on the boards of directors of United Therapeutics Corporation and Mattel Corporation. Dr. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison.

What is Judy D. Olian's net worth?: The estimated net worth of Judy D. Olian is at least $2.06 million as of November 11th, 2024. Dr. Olian owns 5,655 shares of United Therapeutics stock worth more than $2,060,286 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Olian may own. Learn More about Judy D. Olian's net worth.
How do I contact Judy D. Olian?: The corporate mailing address for Dr. Olian and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Judy D. Olian's contact information.
Has Judy D. Olian been buying or selling shares of United Therapeutics?: During the past quarter, Judy D. Olian has sold $721,840.00 in United Therapeutics stock. Most recently, Judy D. Olian sold 1,750 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a transaction totalling $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares of the company's stock, valued at $2,332,574.40. Learn More on Judy D. Olian's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 79 times. They sold a total of 430,475 shares worth more than $126,938,624.54. The most recent insider tranaction occured on November, 11th when COO Michael Benkowitz sold 15,000 shares worth more than $6,109,800.00. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 11/11/2024.

Judy D. Olian Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/11/2024	Sell	1,750	$412.48	$721,840.00	5,655
12/9/2022	Sell	1,010	$282.00	$284,820.00	7,655
4/1/2021	Sell	4,207	$184.96	$778,126.72	9,997
3/17/2021	Sell	2,103	$170.00	$357,510.00	7,893
6/8/2020	Sell	4,510	$124.96	$563,569.60	3,490
6/12/2018	Sell	600	$112.38	$67,428.00

Judy D. Olian Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $364.33

$359.40

$365.67

50 Day Range

MA: $363.86

$339.12

$410.00

2 Week Range

Now: $364.33

$208.62

$417.82

Volume

199,252 shs

Average Volume

398,846 shs

Market Capitalization

$16.27 billion

P/E Ratio

16.00

Dividend Yield

N/A

Beta

0.56

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW